StockNews.AI
SRPT
StockNews.AI
146 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

1. Pomerantz LLP investigates claims against Sarepta for potential securities fraud. 2. Sarepta's stock plunged 27.44% following a death linked to its drug ELEVIDYS. 3. The investigation involves Sarepta's officers regarding possible unlawful business practices. 4. Investors are encouraged to contact Pomerantz for potential class action participation.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The significant stock drop after a death related to ELEVIDYS indicates serious investor concerns. Historical precedents show that negative drug-related news often leads to long-term price declines for pharmaceutical companies.

How important is it?

The investigation and stock price decline pose immediate threats to investor confidence and can affect future fundraising and development.

Why Long Term?

The ongoing investigation and potential implications for future drug approvals could affect SRPT's business outlook. Similar cases have resulted in prolonged negative impacts on stock prices in the biotech sector.

Related Companies

PTC Therapeutics, Inc. (PTCT)Amicus Therapeutics, Inc. (FOLD)Bluebird Bio, Inc. (BLUE)
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 18, 2025, Sarepta issued a press release disclosing the death of “a young man with Duchenne muscular dystrophy . . . following treatment with ELEVIDYS”, Sarepta’s Duchenne muscular dystrophy drug, “having suffered acute liver failure.” On this news, Sarepta’s stock price fell $27.81 per share, or 27.44%, to close at $73.54 per share on March 18, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News